Daniel B Kramer

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc How does medical device regulation perform in the United States and the European union? A systematic review
    Daniel B Kramer
    Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 9:e1001276. 2012
  2. pmc Security and privacy qualities of medical devices: an analysis of FDA postmarket surveillance
    Daniel B Kramer
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 7:e40200. 2012
  3. doi request reprint Long-QT syndrome
    Daniel B Kramer
    Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, USA
    Cardiol Rev 19:217-25. 2011
  4. pmc Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 107:1071-1075.e5. 2011
  5. pmc Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02446, USA
    Heart Rhythm 7:1537-42. 2010
  6. doi request reprint An unusual cause of abnormal intrathoracic impedance in a patient with arrhythmogenic right ventricular cardiomyopathy
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Massachusetts 02215, USA
    Pacing Clin Electrophysiol 34:e60-3. 2011
  7. pmc "Just Because We Can Doesn't Mean We Should": views of nurses on deactivation of pacemakers and implantable cardioverter-defibrillators
    Daniel B Kramer
    Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA, 02215, USA
    J Interv Card Electrophysiol 32:243-52. 2011
  8. pmc Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR
    Daniel B Kramer
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Circ Cardiovasc Qual Outcomes 6:488-97. 2013
  9. ncbi request reprint FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012
    Benjamin N Rome
    Harvard Medical School, Boston, Massachusetts2Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    JAMA 311:385-91. 2014
  10. pmc Resynchronization: considering device-based cardiac therapy in older adults
    Daniel B Kramer
    Hebrew Senior Life Institute for Aging Research, Boston, MA 02215, USA
    J Am Geriatr Soc 61:615-21. 2013

Detail Information

Publications19

  1. pmc How does medical device regulation perform in the United States and the European union? A systematic review
    Daniel B Kramer
    Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 9:e1001276. 2012
    ..Data may be available that identify strengths and weakness of the approaches to medical device regulation in these settings...
  2. pmc Security and privacy qualities of medical devices: an analysis of FDA postmarket surveillance
    Daniel B Kramer
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 7:e40200. 2012
    ..These computing capabilities introduce security and privacy risks, yet little is known about the prevalence of such risks within the clinical setting...
  3. doi request reprint Long-QT syndrome
    Daniel B Kramer
    Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, USA
    Cardiol Rev 19:217-25. 2011
    ..In this review, the pathophysiologic, diagnostic, and prognostic features of long-QT syndromes, as well as recommendations regarding therapy, are reviewed...
  4. pmc Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 107:1071-1075.e5. 2011
    ..In conclusion, patients who have, or are eligible to receive, CIEDs might require improved advance care planning and education regarding the ethical and legal options for managing CIEDs at the end of life...
  5. pmc Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02446, USA
    Heart Rhythm 7:1537-42. 2010
    ..Despite the high prevalence of pacemakers and implantable cardioverter-defibrillators, little is known about physicians' views surrounding the ethical and legal aspects of managing these devices at the end of life...
  6. doi request reprint An unusual cause of abnormal intrathoracic impedance in a patient with arrhythmogenic right ventricular cardiomyopathy
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Massachusetts 02215, USA
    Pacing Clin Electrophysiol 34:e60-3. 2011
    ..The strengths and limitations of intrathoracic impedance are described in the context of the physiology of pregnancy...
  7. pmc "Just Because We Can Doesn't Mean We Should": views of nurses on deactivation of pacemakers and implantable cardioverter-defibrillators
    Daniel B Kramer
    Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA, 02215, USA
    J Interv Card Electrophysiol 32:243-52. 2011
    ..This study aims to identify nurses' concerns about the clinical, ethical, and legal aspects of deactivating cardiovascular implantable electronic devices (CIEDs)...
  8. pmc Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR
    Daniel B Kramer
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Circ Cardiovasc Qual Outcomes 6:488-97. 2013
    ..Little is known about the clinical features, procedural risks, or survival of patients receiving replacement versus new implantable cardioverter-defibrillators (ICDs)...
  9. ncbi request reprint FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012
    Benjamin N Rome
    Harvard Medical School, Boston, Massachusetts2Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    JAMA 311:385-91. 2014
    ..Subsequent changes to approved high-risk devices are implemented via "supplements," which may not require additional clinical testing...
  10. pmc Resynchronization: considering device-based cardiac therapy in older adults
    Daniel B Kramer
    Hebrew Senior Life Institute for Aging Research, Boston, MA 02215, USA
    J Am Geriatr Soc 61:615-21. 2013
    ..Informed decision-making by clinicians, policy-makers, and patients will require greater understanding of the use and outcomes of CRT in older persons...
  11. doi request reprint Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation
    Adam S Fein
    Harvard Thorndike Electrophysiology Institute, Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Am Coll Cardiol 62:300-5. 2013
    ..The aim of this study was to examine the effect of continuous positive airway pressure (CPAP) therapy on atrial fibrillation (AF) recurrence in patients with obstructive sleep apnea (OSA) undergoing pulmonary vein isolation (PVI)...
  12. pmc Deactivation of pacemakers and implantable cardioverter-defibrillators
    Daniel B Kramer
    Hebrew SeniorLife Institute for Aging Research, Boston, MA, USA
    Prog Cardiovasc Dis 55:290-9. 2012
    ..The empirical literature describing stakeholder views and experiences surrounding CIED deactivation is described, along with implications of these studies for future research surrounding the care of patients with CIEDs...
  13. ncbi request reprint Management of cardiac electrical implantable devices in patients nearing the end of life or requesting withdrawal of therapy: review of the Heart Rhythm Society 2010 consensus statement
    Daniel B Kramer
    The Cardiovascular Institute, Beth Isreal Deaconess Medical Center, Harvard Medical School Boston, Massachusetts, United States
    Pol Arch Med Wewn 120:497-502. 2010
    ..In this article, we provide a summary of the HRS guidelines and highlight the most important features of CIED deactivation for the practicing clinician...
  14. doi request reprint Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators
    Daniel B Kramer
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02446, USA
    Heart Rhythm 9:42-6. 2012
    ..Better methods are needed for identifying patients at high risk for early mortality despite ICD therapy...
  15. pmc Approval of high-risk medical devices in the US: implications for clinical cardiology
    Benjamin N Rome
    Program on Regulation, Therapeutics, And Law PORTAL, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, 1620 Tremont St, Suite 3030, Boston, MA, 02120, USA
    Curr Cardiol Rep 16:489. 2014
    ..Clinician and patient engagement in postmarket surveillance and comparative effectiveness research remains imperative...
  16. doi request reprint Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007
    Daniel B Kramer
    Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am J Ther 17:2-7. 2010
    ..Manufacturers, regulators, and the clinical community should collaborate to address these study shortcomings to ensure that patients are treated with reliable, safe, and clinically useful medical devices...
  17. pmc Event-free survival following CRT with surgically implanted LV leads versus standard transvenous approach
    Amy L Miller
    Department of Medicine, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Pacing Clin Electrophysiol 34:490-500. 2011
    ..We hypothesized that surgical procedures would be associated with increased mortality risk...
  18. doi request reprint Cardiac resynchronization therapy for low-flow, low-gradient aortic stenosis
    Yuval Konstantino
    The Cardiovascular Institute, Beth Israel Deaconess Medical Center, Baker 4, 185 Pilgrim Road, Boston, MA 02215, USA
    Eur J Heart Fail 12:889-92. 2010
    ..We discuss the management of this high-operative-risk patient, who ultimately underwent upgrading of his dual chamber pacemaker to a biventricular pacemaker with significant echocardiographic, haemodynamic, and clinical improvement...